首页> 外文OA文献 >P1.01-55 Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer

【2h】

P1.01-55 Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer

机译：P1.01-55通过组织学改造了结果的分析与晚期非小细胞肺癌中的组织学vs细胞学pd-l1 22c3抗体检测

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A. Sathiyapalan; Y. Wang; R. Juergens; M. Butcher; A. Naqvi; J. Cutz;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. P2.09-08 Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer [J] . Y. Wang, M. Butcher, A. Naqvi, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P2.09-08组织学的临床结果与细胞学PD-L1 22C3抗体试验在先进的非小细胞肺癌中
2. The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay [J] . Matthew Evans, Brendan OSullivan, Frances Hughes, Pathology oncology research: POR . 2020,第1期

机译：PD-L1表达在非小细胞肺癌中的临床病理和分子关联：22C3测定检测的10,005例系列分析
3. The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay [J] . Pathology oncology research: POR . 2020,第1期

机译：PD-L1表达在非小细胞肺癌中的临床病理和分子关联：22C3测定试验的10,005例系列分析
4. Gene expression profiles predict survival of patients with advanced non-small cell lung cancers [C] . Harun Roslan, Hadi Jalal, Mhazir Nur Shukriyah, 2011 Fourth International Conference on Modeling, Simulation and Applied Optimization . 2011

机译：基因表达谱预测晚期非小细胞肺癌患者的生存
5. Symptoms Leading to Nutritional Risk in Advanced Non-Small Cell Lung Cancer Patients: The Importance of Nutritional Screening in the Advanced Lung Cancer Population [D] . Swinton, Nelda. 2009

机译：导致晚期非小细胞肺癌患者营养风险的症状：在晚期肺癌人群中进行营养筛查的重要性
6. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? [O] . Vanda F. Torous, Deepa Rangachari, Benjamin P. Gallant, -1

机译：使用克隆22C3 pharmDx试剂盒进行PD-L1测试以选择非小细胞肺癌患者接受免疫检查点抑制剂治疗：细胞学细胞阻断剂是否可行？
7. Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect onEGFRMutation–Positive Lung Adenocarcinoma [O] . Taehee Kim, Yoon Jin Cha, Yoon Soo Chang 2020

机译：22C3和SP263在非小细胞肺癌中测试的PD-L1表达及其预后抗肺腺癌

P1.01-55 Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅